Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Mixed As Australia’s CSL Moves To Settle U.S. Price Fixing Case

This article was originally published in PharmAsia News

Executive Summary

Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.

You may also be interested in...



Grifols To Divest Factor VIII Product Koate To Merge With Talecris

Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.

CSL CEO Brian McNamee On Being Australia's Only Homegrown MNC: An Interview With PharmAsia News (Part 2 of 2)

[Editor's note: This is part two of a two-part interview. Part one appeared in PharmAsia News, June 1, 2009.]

Cynata Sets Stage For Global Fujifilm Cell Therapy Deal

Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142726

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel